JP2024517855A - 融合ポリペプチド - Google Patents

融合ポリペプチド Download PDF

Info

Publication number
JP2024517855A
JP2024517855A JP2023568204A JP2023568204A JP2024517855A JP 2024517855 A JP2024517855 A JP 2024517855A JP 2023568204 A JP2023568204 A JP 2023568204A JP 2023568204 A JP2023568204 A JP 2023568204A JP 2024517855 A JP2024517855 A JP 2024517855A
Authority
JP
Japan
Prior art keywords
fusion polypeptide
polypeptide
metal hydroxide
fusion
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023568204A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024517855A5 (https=
Inventor
シュミット，マイケル
ザルビス－パラストイティシス，グリゴリオス
デイン ヴィットルップ，カール
アーヴィン，ダレル
Original Assignee
アンキラ セラピューティクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アンキラ セラピューティクス，インコーポレイテッド filed Critical アンキラ セラピューティクス，インコーポレイテッド
Publication of JP2024517855A publication Critical patent/JP2024517855A/ja
Publication of JP2024517855A5 publication Critical patent/JP2024517855A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023568204A 2021-05-05 2022-05-04 融合ポリペプチド Pending JP2024517855A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163184620P 2021-05-05 2021-05-05
US63/184,620 2021-05-05
PCT/US2022/027617 WO2022235755A2 (en) 2021-05-05 2022-05-04 Fusion polypeptides

Publications (2)

Publication Number Publication Date
JP2024517855A true JP2024517855A (ja) 2024-04-23
JP2024517855A5 JP2024517855A5 (https=) 2025-05-15

Family

ID=82020825

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023568204A Pending JP2024517855A (ja) 2021-05-05 2022-05-04 融合ポリペプチド

Country Status (8)

Country Link
US (3) US12454695B2 (https=)
EP (1) EP4334337A2 (https=)
JP (1) JP2024517855A (https=)
KR (1) KR20240028341A (https=)
AU (1) AU2022269602A1 (https=)
CA (1) CA3217079A1 (https=)
IL (1) IL308240A (https=)
WO (1) WO2022235755A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4334337A2 (en) 2021-05-05 2024-03-13 Ankyra Therapeutics, Inc. Fusion polypeptides
CA3234552A1 (en) 2021-10-20 2023-04-27 Synthekine, Inc. Heterodimeric fc cytokines and uses thereof
JP2025540624A (ja) * 2022-11-09 2025-12-16 アンキラ セラピューティクス，インコーポレイテッド 融合ポリペプチドを作製する方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019346335B2 (en) * 2018-09-28 2024-07-25 Massachusetts Institute Of Technology Collagen-localized immunomodulatory molecules and methods thereof
WO2020263399A1 (en) 2019-06-26 2020-12-30 Massachusetts Institute Of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
EP4334337A2 (en) 2021-05-05 2024-03-13 Ankyra Therapeutics, Inc. Fusion polypeptides

Also Published As

Publication number Publication date
US20260035706A1 (en) 2026-02-05
WO2022235755A3 (en) 2022-12-29
EP4334337A2 (en) 2024-03-13
CA3217079A1 (en) 2022-11-10
KR20240028341A (ko) 2024-03-05
US20220372495A1 (en) 2022-11-24
US20250327085A1 (en) 2025-10-23
IL308240A (en) 2024-01-01
AU2022269602A1 (en) 2023-11-09
WO2022235755A2 (en) 2022-11-10
US12454695B2 (en) 2025-10-28

Similar Documents

Publication Publication Date Title
EP3638700B1 (en) Proteinaceous heterodimer and use thereof
CN107683289B (zh) IL13Rα2结合剂和其在癌症治疗中的用途
US20260035706A1 (en) Fusion polypeptides
JP2021524740A (ja) 抗ｍｕｃ１抗体
CN114901691A (zh) Ilt3结合剂及其使用方法
RS60996B1 (sr) Interleukin 15 proteinski kompleks i njegova upotreba
JP2022512043A (ja) 合理的に設計された新規なタンパク質組成物
US12552867B2 (en) Single chain fusionconstructs comprising multimeric antibody fragments fused to collagen trimerization domains
KR20170138494A (ko) 항-ｔｙｒ０３ 항체 및 이의 용도
WO2019047885A1 (en) IMMUNOCONJUGATES COMPRISING ALPHA REGULATORY SIGNAL PROTEIN
CN117730102A (zh) 异二聚体Fc结构域抗体
KR102231685B1 (ko) 인간 항-il-32 항체
JP7832689B2 (ja) Ｐｄ－１ポリペプチド変異体
JP2023550191A (ja) Ｄｒ４および／またはｄｒ５を標的とするポリペプチドならびに関連する組成物および方法
CA3170750A1 (en) Serum albumin binding nanobody compositions and methods for using the same
EP3613766B1 (en) Polypeptide improved in protein purity and affinity for antigen, conjugate thereof with antibody or antigen-binding fragment, and preparation method therefor
CN121773135A (zh) 白细胞介素-13受体亚基α-2结合剂和其用途
CN120500541A (zh) 制备融合多肽的方法
KR20250159082A (ko) Nkg2a 결합제 및 이의 용도
KR20250154601A (ko) Nkg2a와 pd-l1에 결합하는 작용제 및 이의 용도
HK40093415A (zh) 具有改善的胞质溶胶穿透活性的抗原结合分子
CN120225554A (zh) Vegf抗体
HK40103919A (zh) 蛋白酶活化的多肽
KR20170027795A (ko) 항-사이토카인 항체의 동정을 위한 인간-유래 항-인간 il-20 항체 및 검정

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250507

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250507